Clinical Trial Update: Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib as second-line therapy in metastatic prostate cancer refractory to androgen blockade was terminated, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Illinois CancerCare, P.C. | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-11-18